

บรรณานุกรม

หนังสือ

วันรักษ์ มิ่งมณีนาคิน. หลักเศรษฐศาสตร์จุลภาค. พิมพ์ครั้งที่ 17. กรุงเทพฯ: โรงพิมพ์ไทยวัฒนา-
พาณิชย์, 2545.

สมคิด แก้วสนธิ และ ภิรมย์ กมลรัตนกุล. เศรษฐศาสตร์สาธารณสุข : การวิเคราะห์และประเมินผล
บริการสาธารณสุข. พิมพ์ครั้งที่ 1. กรุงเทพฯ: โรงพิมพ์จุฬาลงกรณ์มหาวิทยาลัย,
2534.

เอกสารอื่นๆ

สมาคมต่อมไร้ท่อแห่งประเทศไทย. “รายงานวิจัย โครงการลงทะเบียนผู้ป่วยโรคเบาหวาน
(Diabetes registry project 2003)”. 2547.

Books

Drummond MF, O' Brien B, Stoddart GL and Torrance GW. Method for the Economic
Evaluation of Health Care Programes. New York: Oxford University Press Inc.,
1987.

Drummond MF, McGuire A. Economic Evaluation in Healthcare. New York: Oxford
University Press Inc., 2001.

Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and
medicine. 1st edn. New York: Oxford University Press, 1996.

Herfindal ET, Gourley DR. Textbook of therapeutics: drug and disease management (7 ed). Philadelphia: Lippincott Williams & Wilkins, 2000, 377-406.

Articles

American Diabetes Association. "Standards of medical care in diabetes". Diabetes Care Vol.28, Suppl.1 (2005): s4-s36.

Aekplakorn W, Stolk RP, Neal B, Suriyawongpaisal P, Chongsuvivatwong V, Cheepudomvit V, Woodward M. "The prevalence and management of diabetes in Thai adult: The international collaborative study of cardiovascular diseases in Asia". Diabetes Care Vol.26, No.10 (October 2003): 2758-2763.

America Diabetes Association. "Standard of medical care for patients with Diabetes Mellitus". Diabetes Care Vol.25, Suppl.1 (2002): s33-s49.

America Diabetes Association. "Standard of medical care for patients with Diabetes Mellitus". Diabetes Care Vol. 25 (2002): s71-s73.

Chiquette E, Ramirez G, DeFronzo R. "A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors". Arch Intern Med. 164 (2000): 2094-2104.

Cryer P, Davis SN, Shamoo H. "Hypoglycemia in Diabetes". Diabetes Care Vol. 26, No.6 (June 2003): 1902-1912.

Davey P, Price N, Lees M, Makino K, Birinyi-Strachan L, Frost M. "Comparison of reimbursement system of various countries in central and eastern Europe, Africa, Middle East and Asia". ISPOR connection (February 15, 2005).

Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT-EDIC) research group. "Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy". N Engl J Med Vol.342 (2000): 381-389.

Fritsche A, Schweitzer MA, Haring HU. "Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedron insulin, or bedtime insulin glargine in patients with Type 2 diabetes". Ann Intern Med Vol.138 (2003): 952-959.

King H, Aubert RE, Herman WH. "Global burden of diabetes, 1995-2025: prevalence, Numerical estimates, and projections". Diabetes care Vol.21 (1998):1414-1431.

Leese GP, Wang J, Kelly P, Marsden A, Morrison W, Frier BM, Morris AD. "Frequency of severe hypoglycemia requiring emergency treatment in Type 1 and Type 2 Diabetes". Diabetes Care Vol.26, No.4 (April 2003): 1176-1180.

Lindholm A. "New insulin in the treatment of diabetes mellitus". Best practice & Research in Gastroenterology Vol.16, No.3 (2002): 475-492.

Nordfeldt S, Johnson D. "Short-term effect of severe hypoglycemia in children and adolescents with type 1 diabetes. A cost of illness study". Acta Paediatr Vol.90 (2001): 137-142.

- Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA. "The CORE Diabetes Model: Projecting long-term clinical outcomes, cost and cost-effectiveness of interventions in Diabetes Mellitus (Type 1 and 2) to support clinical and reimbursement decision making". Current Medical Research and Opinion Vol.20, Suppl.1 (2004): s5-s26
- Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, Oglesby A, Hayes C, Spinas GA. "What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and cost of complications in patients with Type 2 Diabetes? A projection using the Diabetes CORE model". Current Medical Research and Opinion Vol.20, Suppl.1 (2004): s59-s66.
- Riddle MC, Rosenstock J, Gerich J. "The treat-to-target trial; Randomized additional of glargine or human NPH insulin to oral therapy of Type 2 diabetic patients". Diabetes Care Vol.26, No.11 (November 2003): 3080-3086.
- Rosenstock J, Dailey G, Massi-Benedetti M, Fritche A, Lin Z, Salzman A. "Reduce hypoglycemia risk with Insulin Glargine; A meta analysis comparing insulin glargine with human NPH insulin in Type 2 Diabetes". Diabetes Care Vol. 28, No.4 (April 2005): 950-955.
- Stamler J, Vaccaro O, Neaton JD, Wentworth D. "Diabetes other risk factors and 12-yr cardiovascular mortality for men screened in The Multiple Intervention Risk Factor Trial". Diabetes Care Vol. 16 (1993): 434-444.
- The expert committee on diagnostic and classification of diabetes mellitus. "Report of the expert committee on diagnostic and classification of diabetes mellitus". Diabetes Care Vol.26 (2003): s5-s20.

UK Prospective Diabetes Study Group. "Intensive blood glucose controls with sulfonylureas or insulin compare with conventional treatment and risk of complications in patients with type 2 diabetes" (UKPDS 33). Lancet Vol. 352 (1998): 837-853.

UK Prospective Diabetes Study Group. "Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes". BMJ Vol.317, No.12 (September 1998): 703-713.

Warren E, Weatherley-Jones E, Chilcott J and Beverley C. "Systematic review and economic evaluation of a long-acting insulin analogue, Insulin glargine". Health Technology Assessment Vol.8, No.45 (2004).

Wang F, Carabino JM., Vergara CM., "Insulin Glargine: A systematic Review of Insulin Analogue". Clinical Therapeutic. Vol. 25, No. 6 (2003): 1541-1557.

Yki-Jarvinen H, Dressler A, Ziemer M. "Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes". Diabetes Care Vol.23, No.8 (August 2000): 1130-1136.

Other Materials

Asian-pasific type 2 diabetes policy group. Type 2 diabetes practical targets and treatments, the international diabetes institute (IDI): Melbourne, Australia.

Shulman K. "Clinical Economics" <http://symptomresearch.nih.gov/chapter_12/Part_1/ckspt1authbio.html>. May, 2006.